University of Sydney, Bosch Institute, Camperdown, New South Wales, Australia.
Future Oncol. 2010 Dec;6(12):1897-913. doi: 10.2217/fon.10.149.
Incidences of prostate cancer in most countries are increasing owing to better detection methods; however, prevention with the use of finasteride, a very effective steroid 5α-reductase type II inhibitor, has been met with mixed success. A wide interindividual variation in response exists and is thought to be due to heritable factors. This article summarizes the literature that attempts to elucidate the molecular mechanisms of finasteride in terms of its metabolism, excretion and interaction with endogenous steroid molecules. We describe previously reported genetic variations of steroid-metabolizing genes and their potential association with finasteride efficacy. Based on the literature, we outline directions of research that may contribute to understanding the interindividual variation in finasteride prevention and to the future development of personalized medicine.
由于检测方法的改进，大多数国家的前列腺癌发病率正在上升；然而，使用非那雄胺（一种非常有效的甾体 5α-还原酶 II 型抑制剂）进行预防的效果喜忧参半。人们认为，这种药物的反应存在广泛的个体间差异，这是由于遗传因素造成的。本文总结了试图阐明非那雄胺代谢、排泄及其与内源性甾体分子相互作用的分子机制的文献。我们描述了以前报道的甾体代谢基因的遗传变异及其与非那雄胺疗效的潜在关联。基于文献，我们概述了可能有助于理解非那雄胺预防的个体间差异以及未来个性化医学发展的研究方向。
